Us Congress 2023-2024 Regular Session

Us Congress House Bill HB6094

Introduced
10/26/23  
Refer
10/26/23  

Caption

Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act

Impact

If enacted, HB6094 would require Medicare and Medicaid to provide coverage for specific drugs used in managing rare diseases, ensuring that the criteria for coverage are inclusive of treatments supported by peer-reviewed medical literature and not merely grounded in unfavorable compendia reviews. This change signals a shift towards a more patient-centered approach in healthcare, emphasizing the importance of scientific validation in treatment accessibility. Additionally, the bill mandates expedited review processes for drug coverage denials in private health insurance plans, which could shorten the time patients spend waiting for necessary medications.

Summary

House Bill 6094, also known as the 'Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act' or 'PROTECT Rare Act', aims to amend titles XVIII and XIX of the Social Security Act as well as title XXVII of the Public Health Service Act. The bill's primary focus is to refine the information sources used to determine the coverage of specific drugs and biologicals that are employed in the treatment or management of rare diseases or conditions, particularly those affecting 200,000 or fewer individuals within the United States. This legislation represents a significant step towards improving access to vital treatments that have previously been limited under existing health insurance frameworks.

Contention

Discussion surrounding HB6094 is anticipated to reveal various concerns primarily related to the impact on insurance premiums and the scope of coverage for more common treatments that might compete for funding within existing healthcare resources. Some legislators may argue that the expedited processes might strain insurance resources, while proponents believe that the urgency of treating rare diseases warrants such measures. The bill could foster debates over the allocation of healthcare funds and the prioritization of treatment for rare versus common diseases, highlighting the complexity of balancing individual patient needs against broader healthcare expenditures.

Companion Bills

No companion bills found.

Previously Filed As

US HB3069

John Lewis Equality in Medicare and Medicaid Treatment Act of 2023

US HB5342

Equal Treatment of Public Servants Act of 2023

US HB5601

MORE Act Marijuana Opportunity Reinvestment and Expungement Act

US HB3561

PATIENT Act of 2023 Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023

US HB3892

Improving Mental Health and Drug Treatment Act of 2023

US HB4731

Access to Infertility Treatment and Care Act

US HB4189

CONNECT for Health Act of 2023 Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2023

US SB1582

Opportunities in Organic Act of 2023

US HB2408

Access to Innovative Treatments Act of 2023

US HB8801

MOMS Act More Opportunities for Moms to Succeed Act

Similar Bills

No similar bills found.